- Home
- FDMT
FDMT
4D Molecular Therapeutics Inc.
as 04-17-2025 4:00pm EST
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | N/A | IPO Year: | 2020 |
| Target Price: | $30.29 | AVG Volume (30 days): | 854.0K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.23 - $28.93 | Next Earning Date: | 05-08-2025 |
| Revenue: | $37,000 | Revenue Growth: | -99.82% |
| Revenue Growth (this year): | 13270.27% | Revenue Growth (next year): | -23.06% |
Latest 4D Molecular Therapeutics Inc. News
FDMT Breaking Stock News: Dive into FDMT Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
4DMT Announces New Employment Inducement Grants
TipRanks
16 days ago
Biotech stocks slide as Marks resignation seen being negative for sector
GlobeNewswire
21 days ago
4DMT to Participate in Upcoming Investor Conferences
GlobeNewswire
a month ago
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
TipRanks
a month ago
4D Molecular price target lowered to $35 from $39 at RBC Capital
MT Newswires
a month ago
Chardan Trims Price Target on 4D Molecular Therapeutics to $28 From $30, Keeps Buy Rating
MT Newswires
2 months ago
RBC Lowers Price Target on 4D Molecular Therapeutics to $35 From $39, Keeps Outperform, Speculative Risk
Simply Wall St.
2 months ago
4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations
Compare FDMT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FDMT 4D Molecular Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.